Beijing Minhai Biotechnology Co.,Ltd.is a modern biotechnology enterprise specialized in vaccine R&D, production and distribution. Minhai’s mission is to provide safe, stable and affordable vaccines; increase immunization coverage, reduce the incidence of infectious disease and mortality; protect human health. Minhai was founded in June 2004, with a registered capital of 200 million RMB, at No.35, Simiao Road, Bio-medicine Industry Park in Daxing District, Beijing, which has a leading R&D center and a modern vaccine manufacturing site composed of over 60,000 m2 GMP compliant workshops, equipped with advanced large-scale bacteria vaccine production line and virus vaccine production line. Until 2015, there are three commercialized vaccine products in China, including Hib conjugate vaccine, MR vaccine and DTaP-Hib vaccine. DTaP-Hib vaccine, which is independently developed by Minhai, is the first domestic quatri-valent vaccine. There are over 20 vaccines in Minhai’s pipeline (from pre-clinical trial to NDA), including pneumococcal conjugate vaccine, HDCV rabies vaccine, sabin IPV and meningitis conjugate vaccine etc. In the meantime of developing novel vaccines, Minhai initiated international registration and accelerated the process of export. From 2013, Minhai has started the registration of three marketed products in more than 10 countries including India, Russia and the Philippines, and initiated WHO prequalification preparation. Minhai is enlarging multi-angle, multi-level international collaboration, and extensively promote globalization strategy. Minhai is collaborating and competing with world class vaccine enterprises, working hard to share Minhai’s safe, stable and affordable vaccines with all human beings around the world.